Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Illumina Shares Fall Sharply on Lower Revenue Guidance

Share on Stocktwits


Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance.

In an announcement released this morning, Illumina Inc. (ILMN:NASDAQ) reported lower preliminary revenue for Q2/19 and adjusted annual revenue guidance across three different business areas. The company advised that later this month it expects to report Q2/19 revenue of approximately $835 million, up from $830 million in Q2/18.

The firm advised that Q2/19 results were impacted by approximately $30 million lower revenue than expected associated with population genomics initiatives; $10 million lower revenue than expected associated with ongoing weakness in the direct-to-consumer (DTC) market, primarily array services; and $10 million lower revenue than expected with Illumina's non-high-throughput sequencing systems and consumables. NovaSeq consumable volume growth was up 40% sequentially, and more than 100% year-over-year with system shipments ahead of expectations in the second quarter.

Illumina now expects fiscal year revenue growth of approximately 6%, primarily associated with lower near-term expectations in DTC.

Francis deSouza, president and CEO of Illumina, commented, "We are obviously disappointed with our second quarter financial results. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business." Additionally, the firm advised that in light of the lower revenue growth expectations for 2019 it is taking immediate action to adjust operating expenses for the remainder of the year.

Investors can expect additional details from the firm including full year earnings guidance during the company's upcoming quarterly conference call scheduled for July 29, 2019, at 5:00 pm EDT.

Illumina is based in San Diego, Calif., and describes itself as a global leader in DNA sequencing and array-based technologies fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology and other emerging segments. The company states that is dedicated to improving human health by unlocking the power of the genome. The firm provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Illumina shares have been trading down more than 15% today from yesterday's closing price of $363.66 on higher than average volume. In the first half of the trading day, shares have traded between $305.00 and $312.47/share. With 147 million outstanding, its market cap has taken a hit of around $8 billion today based on the current share price of $308.55.


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe